Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks. Results: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. Conclusions: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.
Abstract
Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods: In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks. Results: Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. Conclusions: For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.
참고문헌 (46)
- "The World Cancer Report: the major findings", Cent Eur J Public Health, 11, pp.177~179 (2003)
- Kotwall C, "Metastatic patterns in squamous cell cancer of the head and neck", Am J Surg, 154, pp.439~442 (1987)
- Zbaren P, "Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy", Arch Otolaryngol Head Neck Surg, 113, pp.762~764 (1987)
- Haddad RI, "Recent advances in head and neck cancer", N Engl J Med, 359, pp.1143~1154 (2008)
- Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
- Specht L, "Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck", Ann Oncol, 11, pp.845~849 (2000)
- Schoffski P, "Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group", Ann Oncol, 10, pp.119~122 (1999)
- Glisson BS, "Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck", J Clin Oncol, 20, pp.1593~1599 (2002)
- Caponigro F, "Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck : a phase II study of the Southern Italy Cooperative Oncology Group(SICOG)", Ann Oncol, 12, pp.199~202 (2001)
- Chen YM, "A randomized trial of different docetaxel schedules in nonsmall cell lung cancer patients who failed previous platinum-based chemotherapy", Chest, 129, pp.1031~1038 (2006)
- Tabernero J, "A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer", Ann Oncol, 15, pp.1358~1365 (2004)
- Charles KA, "Predicting the toxicity of weekly docetaxel in advanced cancer", Clin Pharmacokinet, 45, pp.611~622 (2006)
- Hainsworth JD, "Practical aspects of weekly docetaxel administration schedules", Oncologist, 9, pp.538~545 (2004)
- Ji JH, "A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer(KCSG HN07-01)", Eur J Cancer, 48, pp.3198~3204 (2012)
- Kim YS, "A randomized phase II study of weekly docetaxel", cisplatin versus weekly docetaxel, Cancer Chemother Pharmacol, pp.2014, 73[DOI]
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Pfister DG, "NCCN practice guidelines for head and neck cancers", Oncology(Williston Park), 14, pp.163~194 (2000)
- Benson AB 3rd, "NCCN clinical practice guidelines in oncology : hepatobiliary cancers", J Natl Compr Canc Netw, 7, pp.350~391 (2009)
- Jacobs C, "A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck", J Clin Oncol, 10, pp.257~263 (1992)
- Forastiere AA, "Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck : a Southwest Oncology Group study", J Clin Oncol, 10, pp.1245~1251 (1992)
- Kucukzeybek Y, "Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer", J BUON, 13, pp.199~203 (2008)
- Argiris A, "Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : a phase 2 trial of the Eastern Cooperative Oncology Group", Cancer, 115, pp.4504~4513 (2009)
- Fayette J, "Paclitaxel is effective in relapsed head and neck squamous cell carcinoma : a retrospective study of 66 patients at a single institution", Anticancer Drugs, 21, pp.553~558 (2010)
- Luo Z, "Continuous infusion of 5-FU with split-dose cisplatin : an effective treatment for advanced squamous-cell carcinoma of the head and neck", Clin Invest Med, 34, pp.E8~E13 (2011)
- Won YW, "A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck", Ann Oncol, 22, pp.417~423 (2011)
- Huang YC, "A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma", Jpn J Clin Oncol, 41, pp.630~636 (2011)
- Kafri Z, "Phase II study of gemcitabine and docetaxel combination in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck", ISRN Oncol, 2012, pp.159568~ (2012)
- Briasoulis E, "Weekly docetaxel in minimally pretreated cancer patients : a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration", Ann Oncol, 10, pp.701~706 (1999)
- Miyata M, "The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients", Cancer J, 12, pp.69~72 (2006)
- Goh BC, "Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies", J Clin Oncol, 20, pp.3683~3690 (2002)
- Bosch TM, "Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel", Clin Cancer Res, 12, pp.5786~5793 (2006)
- Cho SH, "Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer", Lung Cancer, 69, pp.94~98 (2010)
- Okamoto H, "Weekly docetaxel treatment for head and neck cancer", Gan To Kagaku Ryoho, 32, pp.1915~1918 (2005)
- Hitt R, "Weekly docetaxel in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck, 2006, pp.106, 106~111
- Cho BC, "Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck", Cancer Chemother Pharmacol, 65, pp.27~32 (2009)
- Specenier P, "Weekly docetaxel in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck, 2011, pp.34, 472~477
- Hong A, "Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer", Eur J Cancer, 46, pp.2088~2096 (2010)
- Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer", N Engl J Med, 363, pp.24~35 (2010)
- Rischin D, "Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02phase III trial", J Clin Oncol, 28, pp.4142~4148 (2010)
- Hannisdal K, "Human papillomavirus(HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway", Acta Otolaryngol, 130, pp.293~299 (2010)
- Chaturvedi AK, "Human papillomavirus and rising oropharyngeal cancer incidence in the United States", J Clin Oncol, 29, pp.4294~4301 (2011)
- Lassen P, "The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer : evaluation of the randomised DAHANCA 6&7 trial", Radiother Oncol, 100, pp.49~55 (2011)
- Hong AM, "Use of cyclin D1in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer", Int J Cancer, 128, pp.1532~1545 (2011)
- Sethi S, "Characteristics and survival of head and neck cancer by HPV status : a cancer registry-based study", Int J Cancer, 131, pp.1179~1186 (2012)
- Deng Z, "Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma", Cancer Sci, 103, pp.2127~2134 (2012)
- Andl T, "Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control", Cancer Res, 58, pp.5~13 (1998)